The data from Part 1 of the ongoing global Phase 1 study ( ZWI-ZW191-101 ), highlight a compelling combination of anti-tumor activity and manageable safety in patients with advanced, heavily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results